When searching for an initial validation of AuNP-BBN-Pt as new tools for the image-guided and selective delivery of Pt(IV) prodrugs to tumor cells and tissues, we have focused on prostate cancer (PCa), as this type of cancer is known to overexpress GRPR in a relatively large percentage of cases. The gene discussed is GRPR; the disease is prostate carcinoma.